慢性肺间质病chronicinterstitiallungdisease-浙江大学.ppt

IFN-? 1b Phase III Results Summary: Preliminary Findings Compelling survival benefit 40% reduction in mortality ITT (p= 0.084) 48% reduction in mortality per protocol (p=0.055) 70% reduction in mortality in FVC 55% (p=0.004) Primary Endpoint The observed 10% relative reduction in disease progression in the treatment arm did not reach statistical significanced Improvement in dyspnea Decreased new use of O2 Safe and well tolerated Safety IFN-? 1b was generally well-tolerated with few discontinuations from AEs Excess of non-fatal pneumonias in IFN-? 1b group Conclusion No medication resulted in objective improvement or stopped the progression of the disease Prednisone therapy was associated with a higher incidence of serious side effects than was colchicine Drugs were relatively ineffective and may not be different than no therapy 小结 IPF的概念、临床特点和诊断方法 鉴别诊断的要点 治疗情况 * * This slide shows the TLC for each patient and the mean (±SD) value for each group before treatment and after 1 year of treatment. Treatment with prednisolone alone did not significantly affect TLC, as shown by the graph on the left, whereas the combination of IFN- ?1 b and prednisolone significantly improved TLC (P0.001), as shown by the graph on the right. The results were similar for the changes in FVC. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block L-H. A preliminary study of long-term treatment with interferon gamma-1 b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 1999;341:1264-1269. Figure adapted with permission from Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block L-H. A preliminary study of long-term treatment with interferon gamma-1 b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 1999;341:1264-1269. Copyright ? 1999. Massachusetts Medical Society. Adapted 2000. All rights * This slide shows the Pa02on maximal exertion for each patient and the mean (±SD) value for each group at b